I could not agree more. There is simply no way that, with such potential, a company like Purdue Pharma will sit back to see what happens with Elite. If Pfizer or another competitor were to either partner or acquire Elite, Purdue will find its 28% market share of the $12 Billion opioid pain med market evaporate. As for their legal efforts to litigate, it is worth remembering they lost to Teva in January and the state of KY is still looming. Besides, litigating for patent infringement is not a growth strategy.